Gustavo Lorenzo Moretta

Dr. Gustavo Lorenzo Moretta

Posgrado Medicina, Universidad San Martín de Porres, Lima, Peru
orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 June 2020 in Clinical Kidney Journal
Verified
Journal Article
Open access
DPDaniela Ponce
Daniela Ponce
ABAndré L Balbi
André L Balbi
JDJonathan B Durand
Jonathan B Durand
Gustavo Lorenzo MorettaGustavo Lorenzo Moretta
Gustavo Lorenzo Moretta
JDJosé C Divino-Filho
José C Divino-Filho
The kidney is not typically the main target of severe acute respiratory syndrome coronavirus 2, but surprisingly, acute kidney injury (AKI) may occur in 4–23% of cases, whereas the dialysis management of AKI from coronavirus 2019 has not gained much attention. The severity of the pandemic has resulted in significant shortages in medical supplies, including respirators, ventilators and personal protective equipment. Peritoneal dialysis (PD) remains available and has been used in clinical practice for AKI for >70 years; however, it has been used on only a limited basis and therefore experience and knowledge of its use has gradually vanished, leaving a considerable gap. The turning point came in 2007, with a series of sequential publications providing solid evidence that PD is a viable option. As there was an availability constraint and a capacity limit of equipment/supplies in many countries, hemodialysis and convective therapies became alternatives. However, even these therapies are not available in many countries and their capacity is being pushed to the limit in many cities. Evidence-based PD experience lends support for the use of PD now.

1 April 2008 in Kidney International
Verified
Journal Article
Closed access
PDF file
Gustavo Lorenzo MorettaGustavo Lorenzo Moretta
Gustavo Lorenzo Moretta
ALA.J. Locatelli
A.J. Locatelli
LGL. Gadola
L. Gadola
JAJ. De Arteaga
J. De Arteaga
LSL. Solá
L. Solá
ZOZ. Ortiz
Z. Ortiz

30 April 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
Gustavo Lorenzo MorettaGustavo Lorenzo Moretta
Gustavo Lorenzo Moretta
RCRosana Chaud
Rosana Chaud
VGValery Tancon Guillén
Valery Tancon Guillén
EMEliana Mateus
Eliana Mateus
Jose Francisco ParodiJose Francisco Parodi
Jose Francisco Parodi
RFRicardo FUJITA
Ricardo FUJITA
Rare diseases pose a growing challenge for health systems due to the combination of high clinical need, limited evidence, and elevated costs. This article analyzes the intersection between translational medicine and pharmacoeconomics, identifying a structural gap between the clinical value of innovations and traditional economic evaluation frameworks. Drawing on a narrative review of the literature—in which 240 scientific articles were identified and the 30 most methodologically and thematically relevant were selected through systematic screening by title, abstract, and full-text relevance—and a comparative analysis of frameworks in Europe, the United States, and Latin America, we propose the concept of translational pharmacoeconomics as an integrative framework that explicitly incorporates clinical, economic, and social dimensions of value into health decision-making. This approach has direct implications for the design of more equitable, adaptive, and sustainable health policies, particularly in contexts of evidence scarcity and unmet clinical need.

16 June 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
JTJavier Torres-Valencia
Javier Torres-Valencia
HBHéctor Luis Bojórquez-Castillo
Héctor Luis Bojórquez-Castillo
JVJanet Fiorella Navarro Vasquez
Janet Fiorella Navarro Vasquez
JPJosías Palza-Valenzuela
Josías Palza-Valenzuela
MCMaría Fernanda Cueva
María Fernanda Cueva
Gustavo Lorenzo MorettaGustavo Lorenzo Moretta
Gustavo Lorenzo Moretta
Background and objectives. Hereditary transthyretin amyloidosis (ATTRv) is a rare, progressive disease caused by deposition of transthyretin-derived amyloid fibrils. Inotersen, an antisense oligonucleotide that inhibits hepatic transthyretin production, is approved by the FDA and EMA but is not fully implemented in low- and middle-income countries (LMICs). We systematically reviewed the evidence on the efficacy, safety and economic impact of inotersen in adults with ATTRv, jointly synthesizing clinical and economic evidence with particular attention to its transferability to LMICs, where treatment access remains limited.Methods. We searched MEDLINE (PubMed), Embase, CENTRAL and SciELO for efficacy and safety evidence, and EconLit, NHS-EED and the CEA Registry (in addition to the clinical databases) for economic evidence (July–August 2025), without language or date restrictions. We followed PRISMA guidelines for reporting our findings. We included randomized controlled trials and economic evaluations with or without economic modelling. Two reviewers screened and extracted data independently, with a senior reviewer for solving discrepancies. Risk of bias was assessed with RoB 2.0 (randomized evidence), ROBINS-I for open-label studies and the Philips and Drummond checklists for economic studies. We synthesised the information retrieved without a meta-analysis.Results. One pivotal trial (NEURO-TTR), reported across five publications including a 170-week open-label extension, and six economic evaluations were included. Inotersen improved neuropathy and quality-of-life outcomes (e.g., mNIS+7 difference −19.7; 95% CI −26.4 to −13.0; Norfolk QoL-DN −11.7; 95% CI −18.3 to −5.1), but serious adverse events — including grade 3–4 thrombocytopenia — were more frequent with inotersen. All economic evaluations adopted a payer perspective; cost-effectiveness ratios were well above conventional thresholds (e.g., ICUR CA$1,322,377/QALY [CADTH reanalysis]; £150,636/QALY [NICE]; €382,984/QALY [NCPE]). Only one study came from a middle-income country (a Mexican budget-impact analysis; US$2.3 million/year, 0.036% of the national health budget) and reported no cost-effectiveness estimate. Risk of bias was moderate for the NEURO-TTR trial and critical for the open-label extension.Conclusions. The evidence favoured inotersen for efficacy and safety in the short term, although long-term evidence is uncertain. Economic studies indicate that inotersen is not cost-effective at current market prices. Evaluation frameworks for rare and orphan diseases are needed to inform the introduction of these therapies where no treatment is currently available, particularly in LMICs.

29 April 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
JTJavier Torres-Valencia
Javier Torres-Valencia
HBHector Luis Bojorquez-Castillo
Hector Luis Bojorquez-Castillo
JVJanet Fiorella Navarro Vasquez
Janet Fiorella Navarro Vasquez
JTJesús Daniel Borja Tovalino
Jesús Daniel Borja Tovalino
EQElder Quispe
Elder Quispe
Gustavo Lorenzo MorettaGustavo Lorenzo Moretta
Gustavo Lorenzo Moretta
Background: Hereditary transthyretin amyloidosis (ATTRv) is a rare multisystemic disease with variable phenotypic expression. No published data exist on the clinical characteristics of ATTRv in Peruvian population.Objective: To describe the demographic, genetic, and clinical characteristics of patients with ATTRv in Peru, and to determine the distribution of clinical phenotypes according to internationally validated criteria.Methods: Descriptive, observational, retrospective case series of patients with ATTRv confirmed by molecular genetic testing, evaluated in Lima, Peru, between 2021 and December 2025 (IMPAC-FE study). Demographic, genetic, neurological (NIS, Norfolk QOL-DN, PND), autonomic (COMPASS-31, SUDOSCAN), and cardiovascular variables (echocardiography, septal thickness, E/e', apical sparing pattern, Tc99m-pyrophosphate scintigraphy, NT-proBNP, troponin) were evaluated. Phenotypes were classified according to AHA/ACC criteria and the THAOS registry.Results: Twenty-three patients were included (69.6% male, median age 60 years, IQR 45-70). The variants were Val142Ile (56.5%), Ala65Val (34.8%), and Val50Met (8.7%). Overall phenotype distribution: preclinical 34.8%, mixed 39.1%, cardiac 21.7%, neurological 4.3%. Norfolk QOL-DN (n=18): median 6.0. COMPASS-31 (n=18): median 6.0. LVEF (n=16): mean 60.5%. LV Mass (n=12): mean 102.9g. Troponin T (n=9): median 47 ng/L. PYP Scintigraphy (n=9): Perugini 3 in 77.8%.Conclusions: This first case series of ATTRv in Peruvian population shows clinical and genetic heterogeneity, with predominance of Val142Ile and Ala65Val variants, and a phenotypic distribution compatible with international registries. The high proportion of preclinical patients and extended cardiovascular evaluation reinforce the need for early diagnosis and timely initiation of disease-modifying therapies.

1 June 2026 in Brazilian Journal of Nephrology
Verified
Journal Article
Open access
CJCelso Souza de Moraes- Júnior
Celso Souza de Moraes- Júnior
NONatalia Orihuela
Natalia Orihuela
NFNatália M.S. Fernandes
Natália M.S. Fernandes
LCLaura Cortés-Sanabria
Laura Cortés-Sanabria
LBLuciane Senra de Souza Braga
Luciane Senra de Souza Braga
JDJosè Divino-Filho
Josè Divino-Filho
Resumo Introdução: As principais ferramentas para a tomada de decisões clínicas baseadas no uso eficiente de recursos são estudos de avaliação econômica que permitem avaliar tanto os custos quanto os benefícios de diferentes terapêuticas, com diretrizes adequadas para a elaboração de relatórios. Este estudo teve como objetivo desenvolver um checklist de elementos de custo de consumo a serem considerados em estimativas para estudos de microcusteio em diálise peritoneal (DP). Métodos: Foram trabalhadas quatro etapas, seguidas de análise e interpretação dos dados. Três etapas foram realizadas para o desenvolvimento do questionário de elementos de custo direto: 1ª – elaboração da primeira versão do checklist; 2ª – avaliação e expansão com a aplicação do método Delphi; 3ª – realização de dois painéis de especialistas; e 4ª – aplicação do questionário a profissionais de 18 países latino-americanos. Critérios de inclusão: profissionais com pelo menos um ano de experiência clínica e/ou administrativa em DP. Foi realizado um ajuste por distribuição de probabilidade discreta. Foram considerados lotes de distribuição por categoria de elementos de custo por país. Aplicou-se o método de estimação por máxima verossimilhança, e a classificação estatística dos ajustes foi estimada utilizando o Critério de Informação de Akaike. Resultados: Foram validados 596 questionários, com sete dimensões e 41 elementos. A partir dos resultados de cada lote, foi possível segmentar os elementos em três opções de escolha, com probabilidade de avaliar um elemento como muito importante, classificando assim os elementos de custo. Conclusão: O checklist favorece um dimensionamento econômico mais equitativo em estudos comparativos, possibilitando a comparação de valores econômicos em DP entre países, considerando os elementos de custo adequados.